PRIMARY ENDPOINT

  • Success in ISGA

SECONDARY ENDPOINT

  • Time to success in ISGA
  • Clear or almost clear

OTHER ENDPOINTS

  • Pruritus
  • Quality of life assessments

For the treatment of mild-to-moderate atopic dermatitis in patients 2 years and older

Significantly more EUCRISA patients achieved success in ISGA at Day 29, the primary efficacy endpoint1-3

Success in ISGA, a stringent metric, is defined as Clear (0) or Almost Clear (1) AND at least a 2-grade improvement from baseline1

ISGA=Investigator's Static Global Assessment.

The Emollient-rich Vehicle control used in clinical studies is the same petrolatum-based, proprietary, nonmedicated ointment formulation in EUCRISA only without the active ingredient crisaborole. Ointments contain emollients which can help lock in moisture and soften the skin.5

Utilizing a vehicle arm is a standard way to test the effect of a topical product. Comparing EUCRISA to the vehicle provided evidence of the effect of the active ingredient, crisaborole, in pivotal trials.

ISGA Scale2
Not an actual patient. For illustrative purposes only.
*Patients with clinical diagnosis of an ISGA of 4, 1, or 0 at baseline were excluded from enrollment.1,2
ISGA=Investigator's Static Global Assessment. The ISGA is primarily used in clinical trials and rarely used in clinical practice.1,3
EUCRISA was studied across a spectrum of patients
See study design

For the treatment of mild-to-moderate atopic dermatitis in patients 2 and older

EUCRISA was studied as monotherapy in both treatment-naïve and treatment-experienced patients3

Actual patient treated with EUCRISA in clinical trials, who achieved success in ISGA, the primary efficacy endpoint.*
All patients may not respond to treatment with EUCRISA. Individual results may vary.

Back to top

References

  1. EUCRISA® (crisaborole) Full Prescribing Information. December 2018.
  2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
  3. Data on File. Pfizer Inc., New York, NY.
  4. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AV. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659-664.
  5. Waters A, Sandhu D, Beattie P, Ezughah F, Lewis-Jones S. Severity stratification of Children's Dermatology Life Quality Index (CDLQI) scores. Br J Dermatol. 2010;163(suppl 1):121.
  6. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984-992.
  7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQl)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
  8. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AV. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33.
  9. Schünemann HJ, Guyatt GH. Commentary goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res. 2005;40(2):593-597.
  10. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase Ill randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64-70.
  11. Lewis-Jones MS, Finlay AV. The children's dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;19(3):210-216.
  12. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.
  13. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.